In its third-quarter 2024 earnings report, Sangamo announced significant achievements, including a regulatory pathway for accelerated approval of a Fabry disease treatment and promising collaborative ...
Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...
Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US ...
RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...
BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche ...
Aris has signed Emmy-nominated Indian-American director Zoe Malhotra, marking her first exclusive representation deal in the ...
Reports Q3 revenue $29.4M, consensus $26.55M. “This is a pivotal time for Sangamo (SGMO) as we build upon our recent strong momentum with ...
"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...
Wyatte Grantham-philips, The Associated Press Nov 12, 2024 9:13 AM Nov 12, 2024 9:35 AM FILE - 23andMe CEO Anne Wojcicki ...
23h
Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback